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Recurrent Aphthous Ulcer (RAU) is a common oral pathology 
that produces pain which affects the lifestyle of the patient. Its 
aetiology and pathogenesis still remain unclear. A considerable 
number of treatments are available with the main goal directed 
towards pain relief. Previous studies on RAU treatment using 
low level laser therapy (LLLT) show immediate pain relief after 
application. Aim: This study aims to evaluate and compare 
treatment effectiveness in relieving pain provided by Waterlase 
(BIOLASE) LLLT and conventional topical corticosteroid using 
Triamcinolone Acetonide 0.1% dental paste. Methods: Thirty 
(30) volunteered patients of age between 18-27 years old were 
divided into two groups. Each group consists of 15 patients with 
7 males and 8 females. Group 1 patients were treated by using 
LLLT while group 2 patients were treated by using triamcinolone 
acetonide 0.1%. The patient’s details, pain intensity and clinical 
photographs were recorded in a specially prepared case sheet. 
Mann-Whitney U test was used to compare significance in pain 
reduction provided by both methods of treatment. Results: 
Both groups showed significant pain reduction immediately, 
day 3 and day 7. Higher reduction in pain intensity was observed 
immediately (p=0.001) and 3 days (p=0.002) after treatment 
in group 1 patients (LLLT) compared to group 2 patients 
(triamcinolone acetonide 0.1%). Conclusion: Waterlase 
(BIOLASE) LLLT is clinically more effective in relieving pain 
compared to Triamcinolone Acetonide 0.1%. 
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Introduction
Recurrent aphthous ulceration (RAU) a common oral mucosal disease. Prevalence 
varies from 5% to 20% and has a predilection towards female. Generally, RAU presents 
as single or multiple, flat, ovoid or round ulceration on the oral mucosa. The lesion has 
characteristic appearance of yellow-white fibrinopurulent membrane surrounded by 
thin erythematous halo. Typically, RAU occurs in the nonkeratinized part of the oral 
mucosa most often appearing at the buccal and labial mucosa followed by ventral 
surface of the tongue, mucobuccal fold, floor of the mouth and soft palate. The recur-
rence rate of RAU varies from one to two episodes per month1. It has a characteristic 
prodromal burning sensation lasting 2-48 hours before ulcer appearance. The ulcer 
results in damaged oral mucosal epithelium with exposed nerve endings causing pain 
and discomfort to the patient. The latter affects the patient’s quality of life by dimin-
ished ability to eat, drink and maintain a good oral hygiene2.
RAU can appear in three forms; minor, major and herpetiform. Several clinical 
presentation criteria such as size, number, localization and duration of lesion are 
used to distinguish between the three different forms. Minor type appears most 
commonly. It is characterized by single or multiple (1-5) lesions of less than 1cm 
in diameter and heals within 7 to 10 days without scarring. Typically it heals within 
1 to 2 weeks with scarring3. The aetiology of RAU remains unclear. However, sev-
eral factors such as genetic, trauma, immunological factor, haematological or 
nutritional deficiencies, menstruation cycle, upper respiratory infection and psy-
chological stress have been proposed that render an individual more susceptible 
to develop RAU4.
Therapy for RAU aims to relieve pain and promote healing. Despite the availability of 
several treatment modalities in the objective to reduce patient’s discomfort and pain, 
an immediate therapeutic regimen is yet to be provided5. Several treatment options 
are available, however the main stay of RAU treatment uses topical corticosteroids. 
Topical corticosteroids are formulated in paste form such as Triamcinolone Aceton-
ide 0.1%, act by limiting the inflammatory process associated with the lesion and 
provide a temporary symptomatic relief. The paste is to be applied 3-4 times daily 
directly onto the lesion to form a protective film. Conventional method however is 
rather symptomatic than curative6.
Low level laser therapy (LLLT) uses low power laser to modulate inflammatory 
response which reduces edema and pain while enhancing cellular biostimulation7. 
Studies have suggested that LLLT could be a positive alternative or adjunct treatment 
that provides immediate pain relief in RAU patients7–9.
Albrektson et al.10 (2014) concluded that LLLT proves to be more superior to Fito-
stimule Gel in treating aphthous ulcer. Use of LLLT to treat chronic RAU is claimed 
to be a reliable therapeutic modality and showed greater efficacy than pharmaco-
therapy11. Aggarwal et al.12 (2014) concluded that LLLT is a safe and effective treat-
ment options in treating aphthous ulcer. Application of LLLT enhances the speed of 
wound healing, provides significant analgesia, and cause no major side effects to 
the subjects treated13.
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MATERIALS AND METHODS
This research is a done on volunteered patients referred the oral medicine clinic 
in Kulliyah of Dentistry, IIUM. Subjects received a full disclosure of the nature of 
the study with an extended opportunity to ask questions prior and throughout 
participation. Informed and written consent were obtained and recorded patient’s 
data were kept in confidentially for research purposes only. Ethical approval 
was obtained from IIUM Research Ethics Committee (IREC) (REF NUMBER: 
IIUM/504/14/11/2/ IREC 705) .
Patient selection
The subjects are volunteered patients who presented to the oral medicine clinic with 
a complaint of pain from RAU. Full history taking and examination were done by the 
operator and presented to the supervisor (specialist). Patients with confirmed diagno-
sis of RAU were selected.
Sampling Method and Sample Size
This is a pilot study, a total of 30 patients ( 14 male and 16 female )in which all are 
Malays who attended the oral medicine clinic at Kulliyyah of Dentistry, IIUM were 
divided into two groups. Group 1 consisting of 15 patients were treated with LLLT 
while group 2 consisting of 15 patients were treated with triamcinolone acetonide 
0.1% dental paste. Exclusion criteria: Patients through history and examination with 
known: ,Smoking, Systemic disease , Immune compromised patients, Pregnancy
Methodology
Patients were asked to rate the pain of the ulcer during the visit using Numerical Rat-
ing Scale (NRS-11) prior to treatment.
Group 1 consist of 15 patients referred to the oral medicine specialist clinic. Prior 
to LLLT application, patients were seated on the dental chair, full personal protective 
equipment (PPE) always worn by the operator and the assistant. Protective eyewear 
were worn by the operator, assistant and the patient to prevent potential damage by 
the reflective energy from the laser irradiation. The type of laser used was Er, Cr: YSGG 
laser by Waterlase MD, Biolase, Irvine, CA, USA. The laser unit was set at 0.5 W - 30 Hz 
for low level energy with 20% air and without water coolant spray. The laser beam 
was applied on the ulcer lesion for 30 seconds with continuous circular motion. The 
distance between the laser tip and the surface of the ulcer was maintained at about 
5mm throughout application of single unit dose. 
Group 2 consisting of 15 patients were treated with triamcinolone acetonide 0.1% 
dental paste. The surface of the ulcer was dried using a sterile gauze and the 
paste was applied using a cotton roll to form a thin film over the lesion surface. 
Patients were instructed to apply the paste twice daily; before a meal and before 
bed for 7 days.
Patients from both groups were instructed to refrain from using any other type of med-
ication to relief the ulcer pain for a period of 7 days. The pain score of the ulcer was 
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evaluated immediately, after 3, and 7 days. Follow up by using NRS-11 together with 
photographic record of the lesion., all data were collected into a special case sheet . 
Data analysis
The collected data were analysed using SPSS software version 21. Intragroup and 
intergroup comparisons were evaluated using Wilcoxon Signed Rank Test and Mann 
Whitney U test respectively.
RESULTS 
Demographic profile was presented in terms of category, frequency and percentage. 
For reliability of the sample, based on Cronbach’s alpha, the reliability is 0.681 which 
is inacceptable scale (Table 1). Coefficient of alpha between 0.5 to 0.8 is considered 
an acceptable level of internal reliability for scales, where group comparisons are to 
be made.
Table 1. Demographic profile
Category Frequency Percentage (%)
Gender
Male
Female
Total
14
16
30
46.7
53.3
100
Age
18 – 22 years old
23-27 years old
Total
8
22
30
26.7
73.3
100
Type of Treatment
LLLT
Triamcinolone Acetonide
Total
15
15
30
50
50
100
Number of Ulcer
Single
Multiple
Total
22
8
30
73.3
26.7
100
Type of Ulcer
Minor
Major
Total
30
0
30
100
0
100
The Mean pain score based on type of treatment immediately, on day 3 and day 7 
after LLLT application is lower compared to Triamcinolone Acetonide by which laser 
shows more pain score reduction compared to Triamcinolone Acetonide. After 7 days 
of treatment, complete pain relief was observed in LLLT group compared to Triamcin-
olone Acetonide group which still has some degree of pain (Figure 1)
Significant difference in pain reduction is evident immediately (<0.001) and 3 days (0.002) 
after treatment when mean pain score of LLLT and Triamcinolone Acetonide groups are 
compared. However, no significance difference in pain reduction is noted 7 days post 
treatment (Calculated using Wilcoxon Signed Rank Test ---- intragroup comparison). 
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Table 2 and 3 show no significant difference in pain reduction in patients of different 
gender (p>0.05) and age groups (p>0.05).
Table 2. Comparison between mean reductions of pain score between genders
Reduction of 
Pain Score
LLLT Triamcinolone Acetonide
Male 
versus 
Female
Male Female
p-value*
Male Female
p-value* p-value*
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Before Treatment
(Baseline) - - - - - - -
Immediately 
After Treatment 3.86 ± 1.574 3.13 ± 1.808 0.463 1.29 ± 1.254 1.13 ± 0.641 0.779 0.578
3 Days After 
Treatment 5.00 ± 1.633 4.38 ± 2.066 0.779 2.71 ± 1.254 2.5 ± 1.852 0.694 0.751
7 Days After 
Treatment 5.71 ± 1.799 5.38 ± 1.302 0.613 3.05 ± 1.799 4.38 ± 1.685 0.779 1.00
Table 3. Comparison between mean reduction of pain score between age group
Reduction of 
Pain Score
LLLT Triamcinolone Acetonide
18-22 
years old 
versus 
23-27 
years old
18 – 22 
years old
23-27 
years old p-value*
18 – 22 
years old
23-27 
years old p-value* p-value*
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Before Treatment
(Baseline) - - - - - - -
Immediately 
After Treatment 3.25 ± 0.957 3.55 ± 1.916 0.463 1.00 ± 0.816 1.27 ± 1.009 0.661 0.578
3 Days After 
Treatment 4.75 ± 1.500 4.64 ± 2.014 0.779 2.75 ± 2.217 2.55 ± 1.368 0.851 0.751
7 Days After 
Treatment 5.75 ± 1.258 5.45 ± 1.635 0.613 4.75 ± 1.708 4.45 ± 1.753 0.753 1.00
*Calculated using Mann Whitney U Test (Sig p <0.05) 
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Figure 1. Mean pain score before treatment, immediately, on day 3 and day 7 after treatment.
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Figure 2. Treatment with LLLT
Day 7 follow up Day 3 follow-up
Immediately after LLLT Pre-LLLT application
Figure 3. Treatment by Triamcinolone Acetonide 0.1%
Before application Immediately After application
Day 3 follow up Day 7 follow up
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DISCUSSION
The present result shows that LLLT is more effective in relieving pain in RAU patients 
compared to treatment with a topical corticosteroid. Application of LLLT provides sig-
nificant pain reduction immediately, 3 days, and 7 days after treatment. This finding 
is in accordance to a controlled study conducted by Aggarwal et al.12,14, which has a 
mean pain reduction of 4.79±0.86 immediately post-LLLT and 4.72±1.22 on day 3 of 
follow up. Similar result was reported by Prasad and Pai13,15 with the mean pain score 
in the laser group immediately after treatment (0.68 ± 0.6) compared with pretreat-
ment (8.48 ± 0.71; P < .001).
However, Sattayut et al.16 (2013) found that no significant pain relief was observed 
immediately but only after 3 days of treatment compared to a placebo group. Fur-
thermore, pain reduction in patients treated by Triamcinolone Acetonide 0.1% dental 
paste was also significant immediately, 3 days, and 7 days after treatment. The latter 
replicates the result of an randomized controlled trial study conducted by Deshmukh 
and Bagewadi17 that showed significant pain reduction from day 0 to 7 after its appli-
cation. The fact that both treatments significantly reduce pain intensity could suggest 
both can be a viable treatment option in treating RAU patients. 
However, intergroup comparison showed significantly higher pain reduction in 
patients treated using LLLT compared to Triamcinolone Acetonide 0.1% immediately 
and on day 3 after the treatment. A comparative study conducted by Deshmukh RA 
(2014) comparing Nd:YAG laser and Triamcinolone Acetonide 0.1% reported similar 
findings with significant difference in pain relief on day 1 (P <0.05) and day 4 (P <0.05) 
after treatment17. In contrast to another comparative study by De Souza et al.18 (2010), 
no statistically significant difference was noted between groups, however 86.60% 
of the patients treated with laser reported a reduction in pain in the same session 
(p¼0.0006). On day 7 after the treatment, the difference was not significant because 
the ulcers were most likely healed and there were very little to no pain by the time the 
patients were asked to rate the pain intensity of the lesion. Since the result of present 
study shows better pain reduction in RAU patients could be achieved by treatment 
using LLLT, practicing clinicians may choose LLLT as a positive alternative treatment 
to conventional topical corticosteroids in treatment of recurrent oral ulceration.
All subjects in this study presented with minor type of RAU. High prevalence of minor 
type in this study coincides with an epidemiological update in Malaysia by De Souza et 
al (2010)18. There was no significant difference in pain reduction observed in patients 
of different gender and age groups.
Unlike many studies on laser treatment efficacy, Numerical Rating Scale(NRS-11) was 
used in this study instead of Visual Analogue Scale(VAS) principally to allow ease 
for follow-up. Since follow up is not possible on the dental chair on certain situa-
tions especially on weekends, the use of NRS-11 allows evaluation of patients, pain 
intensity through phone calls. According to a systematic review by Hjermstad et al.19 
(2011), NRS when compared to VAS and VRS has a higher compliance rate, better 
responsiveness, ease of use and good applicability.
Triamcinolone Acetonide 0.1% dental paste is a synthetic topical corticosteroid 
used in the conventional treatment of RAU. It is administered as a pomade in 
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orabase when the lesion is localized or in rinse format when lesions are diffuse20-23. 
The emollient paste serves as an adhesive vehicle to deliver the active medication 
to the oral tissue. It provides a temporary protective layer that isolates the surface 
of the ulcer from the oral environment thus reducing pain associated with irritation. 
On cellular level, anti-inflammatory effect of Triamcinolone Acetonide is provided by 
reduced cellular membrane permeability, impaired lysosomal enzyme release, and 
inhibition of various chemical mediators released during inflammatory process. It 
also interferes with the migration of PMNL through the walls of blood capillary in 
addition to decreased WBC adherence to capillary endothelium. Interference in the 
normal functioning of lymphocytes and macrophages also contributes to its anti-in-
flammatory effect. 
According to a systematic review by Han et al.11 (2016), the mechanisms of LLLT 
are still not clearly understood. However, several theories are available at present. 
Pain relief after laser irradiation may be provided by photobanding, whereby there 
is formation of a protective layer on the exposed connective tissue of the ulcer23. 
The heat generated from the laser helps to seal small blood and lymphatic vessels 
hence reducing bleeding and edema. The coagulum formed from the laser action 
which comprises of denatured proteins in the tissues and plasma acts as a wound 
protection from friction and bacterial invasion. After 48-72 hours of photobanding, 
the protective layer becomes hydrated, swollen and disintegrates revealing an early 
healing bed of new tissue24. This layer provides a barrier from the oral environment 
and reduces pain that derives from inflammatory sensitization of small-diameter 
afferent nerve endings that form plexus and extend upwards into the epithelial layer. 
Pain relief is also related to the enhanced ATP synthesis in the mitochondria of 
the neurons. Increased ATP synthesis causes hyperpolarization which increases 
the threshold of triggering an action potential thus reducing the induction of pain 
stimuli25. Furthermore, relief of pain can be associated with the inhibition of interleu-
kin-1Beta and prostaglandin E2 that function to lower the pain receptor threshold if 
it becomes accumulated26.
With immediate pain relief and faster wound healing, the use of laser greatly enhances 
patient’s satisfaction and gives positive impact in improving the quality of life. To the 
best of our knowledge, no research has been done in Malaysia to compare the effec-
tiveness of LLLT and Triamcinolone acetonide 0.1% dental paste in treating patients 
with RAU.
In conclusion, pain from RAU reduces patients’ quality of life. Immediate pain relief 
should be the main goal of any treatment modalities proposed. The results of the 
present study support the theory that LLLT promotes pain relief. The effectiveness of 
LLLT in relieving pain in RAU patients may provide clinicians with a positive alternative 
mode of treatment to reduce chairside time as well as to enhance the quality of dental 
service to the community. Further studies with different laser parameters should be 
conducted to establish an ideal protocol for RAU treatment using LLLT. The promising 
results of present study need to be supported by a larger sample size and compar-
ative studies done using other treatment modalities. Moreover, the fact that Malays 
were the only race used as samples, future studies could include other races such as 
Chinese and Indians as well.
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